The Value of Microbes in Cancer Neoantigen Immunotherapy

• Published in: Pharmaceutics Vol. 15; no. 8; p. 2138
• Main Authors: Tian, Junrui, Ma, Jian
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.08.2023; MDPI
• Subjects: Algorithms; Antigens; Cancer; cancer immunotherapy; cancer vaccines; Development and progression; Drug therapy; Genetic engineering; Identification; immune checkpoint inhibitors; Immune system; Immunotherapy; Ions; Mass spectrometry; microbes; Microbiota (Symbiotic organisms); Mutation; Peptides; Proteins; Researchers; Review; Scientific imaging; T cells; Tumor antigens; tumor neoantigen; Vaccines
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15082138

Tumor neoantigens are widely used in cancer immunotherapy, and a growing body of research suggests that microbes play an important role in these neoantigen-based immunotherapeutic processes. The human body and its surrounding environment are filled with a large number of microbes that are in long-term interaction with the organism. The microbiota can modulate our immune system, help activate neoantigen-reactive T cells, and play a great role in the process of targeting tumor neoantigens for therapy. Recent studies have revealed the interconnection between microbes and neoantigens, which can cross-react with each other through molecular mimicry, providing theoretical guidance for more relevant studies. The current applications of microbes in immunotherapy against tumor neoantigens are mainly focused on cancer vaccine development and immunotherapy with immune checkpoint inhibitors. This article summarizes the related fields and suggests the importance of microbes in immunotherapy against neoantigens.